Innovative Leadless Cardiac Pacing IP Portfolio Available for Auction by ICAP Patent Brokerage
MENLO PARK, Calif., March 6, 2013 /PRNewswire/ – ICAP Patent Brokerage announces for auction an IP package of leadless cardiac pacing devices from Magnetic Pacing Technologies GmbH and the University of Duisburg-Essen. This lot will be included in the 18(th) ICAP Ocean Tomo IP Auction on March 20, 2013, at the Rosewood Sand Hill Hotel in Menlo Park, California.
“We are excited to be offering this improved medical device technology to our global base of buyers. This is an important portfolio for companies working in the domain of cardiac rhythm management (CRM), with applications for the pacing, heart failure, and defibrillation markets,” says Dean Becker, CEO of ICAP Patent Brokerage.
Key Characteristics & Benefits
Cardiac pacing has recently become the focus of scientific interest due to a growing medical and market need for improved treatment devices such as leadless defibrillation systems. The portfolio for sale includes important IP covering leadless pacing devices. The available IP package can be utilized alone or in combination with subcutaneous leadless defibrillator systems currently available, and is also highly applicable to internal programs at medical device companies and respected medical research institutions.
The disclosed devices are energy efficient and eliminate the need of electrical leads or probes. The technology does not require active electronics to be implanted into the heart so there are no batteries to charge or active circuits that could fail. Further, these devices may also be tuned for multiple frequencies making it suitable for leadless multi-site pacing. These devices include small-sized receivers for receiving electrode signals, which results in increased surgical options and reduced size of devices. Further, the disclosed technology is compatible with existing cardiac rhythm management devices such as Cardiac Resynchronization Therapy Defibrillators (CRT-D). Most importantly, the disclosed technology can be used with new subcutaneous defibrillators (sICD) to bring pacing back to these sICD’s, a much needed clinical advantage.
See this technical description of the leadless cardiac pacing IP sales offering.
To learn more about the assets available for sale in this portfolio:
Contact John Pryor of ICAP Patent Brokerage at +44(0)7587885131 or via email at John.Pryor@icap.com.
Visit our website to make a patent submission for the auction.
About ICAP Patent Brokerage
ICAP Patent Brokerage is a division of ICAP plc and the world’s largest intellectual property brokerage and patent auction firm.
ICAP is the world’s leading interdealer broker and provider of post trade risk and information services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, FX, emerging markets and equity derivatives through voice and electronic networks. Through our post trade risk and information services we help our customers manage and mitigate risks in their portfolios. For more information, go to www.icap.com.
SOURCE ICAP Patent Brokerage